Hepatitis C Articles	Top
Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers Three New STAT-C Agents Show Promise in Preclinical Studies and Early Clinical Trials: MK-7009, ANA598, and IDX375 Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers HCV Protease Inhibitor ITMN-191 (R7227) Demonstrates Antiviral Potency in Genotype 1 Patients; New ITMN-5489 Also Under Study R7128 plus ITMN-191 Perform Well in Laboratory Study; STAT-C Combination Clinical Trial Now Underway HCV Protease Inhibitor Telaprevir (VX-950) Continues to Perform Well in PROVE Trials Experimental HCV Protease Inhibitor TMC435350 Demonstrates Favorable Safety and Efficacy in Phase 2a Trial Investigational HCV Protease Inhibitor BI 201335 Exhibits Promising Antiviral Activity HCV Polymerase Inhibitor PF-00868554 Inhibits Viral Replication in Treatment-naive Patients IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia Several “STAT-C” Agents Discussed at the Liver Meeting HCV Protease Inhibitor Boceprevir plus Pegylated Interferon/Ribavirin Increases Sustained Virological Response Rate: SPRINT-1 Study
Hepatitis B Articles	Top
Baseline CD4 Cell Count Predicts HBV DNA Decline in HIV Negative and HIV Positive Patients Treated with Adefovir (Hepsera) Hepatitis B Virus Genotype Influences HBV Viral Load and Liver Fibrosis Progression Simvastatin (Zocor) Is Active against Wild-type and Drug-Resistant Hepatitis B Virus Adding Ribavirin Does Not Improve Response to Pegylated Interferon for Chronic Hepatitis B Rescue Therapy with Entecavir (Baraclude) plus Tenofovir (Viread) Is Safe and Effective for Cirrhotic Hepatitis B Patients with Prior Treatment Failures Tenofovir (Viread) Produces Continued HBV Suppression through 96 Weeks in HBeAg Positive and Negative Patients: Studies 102 and 103 Long-term Entecavir (Baraclude) Reverses Liver Fibrosis in HBeAg Positive and HBeAg Negative Chronic Hepatitis B Patients
HIV-HCV and HIV-HBV Coinfection Articles	Top
Baseline CD4 Cell Count Predicts HBV DNA Decline in HIV Negative and HIV Positive Patients Treated with Adefovir (Hepsera) Hepatitis B Virus Genotype Influences HBV Viral Load and Liver Fibrosis Progression Does Antiretroviral Therapy Reduce Ribavirin Levels in HIV-HCV Coinfected Individuals? Partial Rapid Virological Response Predicts Sustained Response in HCV-HIV Coinfected Patients, APRICOT Analysis Shows Outcomes of Acute Hepatitis C Virus Infection in People with HIV Tenofovir (Viread) for Patients with HIV-HBV Coinfection Liver Fibrosis Progression in HIV-HCV Coinfected Individuals
CME Programs	Top
CME Slide Deck Interactive Case Study Discussions on the Treatment of HBV Program Details      CME Talking Slides Update Post AASLD 2008 CME Talking Slides Update Program Details      CME/CE Newsletter Update Post AASLD 2008 CME/CE Newsletter Update Program Details

The material posted on HIV and Hepatitis.com about AASLD 2008 is
not approved by nor is it a part of AASLD 2008.

AASLD 2008 Coverage by HIV and Hepatitis.com

AASLD 2008 Coverage by HIV and Hepatitis.com

AASLD 2008 Coverage by HIV and Hepatitis.com

AASLD 2008 Coverage by HIV and Hepatitis.com